We focus on finding great investment opportunities with innovative and inventive technologies and partners
Turning ideas into reality
We help entrepreneurs with brilliant ideas develop their company to its maximum potential
Partnering with peers
We co-invest with like-minded entrepreneurial families and larger investors to capitalize on combined networks and expertise
Kinled was founded in 1980 to retain the investment assets of the Aisher family.
In 1990, the investment focus shifted to a portfolio of early stage investments applying Kinled’s company development experience alongside the endurance and passion of family owned investments together with the strategic focus of venture capitalists.
Since then, Kinled has taken 8 companies to public markets and many more to successful trade sales at significant multiples.
Kinled Holding was founded in 1980 to retain the investment assets of the Anglo-Austrian branch of the Aisher family.
Manufacturing and Innovation
The family have been directly involved in the manufacturing and development of concrete building materials technology industry since 1920.
Their principal company, Marley PLC, was floated on the London Stock Exchange in 1935 and remained under family management for 60 years. Kinled sold its shareholding when Etex Group of Belgium acquired the business in 1998 for £365 Million.
In the early 1950’s the family invested heavily into the production of plastics for the building industry, resulting in the launch of a separate family-owned business which was eventually sold to the listed company in 1955. As a result of a de-merger in 2003 Marley Plumbing and Drainage Ltd is now integrated within Aliaxis Group, a leading global manufacturer of plastic fluid handling systems with in excess of €2B in revenues.
In the 1960’s another family-controlled business, British Moulded Fibres, became one of the leading manufacturers of automotive moulded fibres, specifically working on instrument panels and interior trim for Ford, GM, and Nissan, with manufacturing in the UK and the Netherlands. Later in 1996, this was sold to Magna International for $74M.
During the 1960’s the family directors also opened a succession of do-it-yourself stores under the Payless brand, which became one of the UK’s leading retailers. Later in 1985, this was sold to Boots for £89M and re-branded as Do-it-All (now Focus/Wickes).
Kinled was a significant shareholder in MDL Group Limited. Founded in 1973, the company grew to become the largest owner/operator of yacht marinas and associated real estate in the United Kingdom. This was successfully listed on the London Stock Exchange in 1985.
In the 1980’s the family directors expanded heavily into North America, acquiring General Shale Corporation, one of the largest brick, stone, and concrete block manufacturers in the USA. This was later acquired in 1999 by Wienerberger Group for $260M.
Kinled has been an active land developer undertaking significant real estate developments in the United Kingdom, Bahamas, Spain, Zimbabwe, Australia. It currently retains interests in a number of tourism/leisure investments and hotel projects in Africa, Argentina, Canada and Switzerland.
In 1990 Kinled made significant private investments in the software, aerospace and mapping technology industries, ultimately exiting in 2008 via a trade sale to the market leader. In 2010 a portfolio of specialised niche engineering firms were acquired. These were re-invigorated with additional capital and management experience before being sold in 2014 for over $15M.
Leisure & Luxury
As of 2000, Kinled also made successful investments in high end luxury goods, including holdings in watch manufacturing (exited via NASDAQ listing in 2002), whisky and wine production, award-winning manufacturers of premium ski and golf sports equipment, audio systems and motorcycles.
Kinled began to focus on medical investments in 1997 when we partnered with a specialised New York-based biotechnology investor, which listed on the NASD in 2003. Since then we have invested in 15 seed or early stage life science businesses. We have exited two via IPO at $17M and $40M, one via trade sale at $150M+ and two via international licensing transactions valued at $350M+.
Kinled today is primarily a life sciences and technology investor. We are particularly interested in neurological solutions and focus on both device and pharmaceutical investments. We currently hold equity in twelve companies in this sector, including Aleva Neurotherapeutics SA, Oxford BioTherapeutics Ltd, Neuro RX Pharma and Iproteos SA, among others.
Kinled Holdings also include small participations in two publicly listed businesses we believe are at the cutting edge of medical development:
Esperite is a diversified biotech global group leader in regenerative and precision medicine. It transforms the power of state-of-the-art technologies and scientific advancements into high quality products to bring the future of medicine to customers today at affordable prices.
A clinical stage company developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases.